AG真人官方

ProKidney Corp. (PROK) filed a Post-Effective Amendment No. 1 to its previously effective Form S-4 on 3 July 2025 to reflect the company鈥檚 completed domestication from the Cayman Islands to Delaware, which became effective 1 July 2025. The amendment, submitted under Rule 414(d), formally adopts the earlier Cayman Islands registration statement as the successor Delaware issuer鈥檚 own, avoiding any lapse in Securities Act or Exchange Act coverage.

Key points for investors:

• Corporate domicile change: The legal entity is now a Delaware corporation governed by the DGCL, its new certificate of incorporation and by-laws. Delaware鈥檚 well-established case law may enhance predictability around shareholder rights and M&A activity.
• Capital continuity: Every Class A and Class B ordinary share of the Cayman entity automatically converted 1-for-1 into the same class of Delaware common stock with identical proportional equity interests; no dilution or change in share count occurred.
• Listing & identifiers: Shares continue trading on Nasdaq Capital Market under ticker 鈥淧搁翱碍鈥�; however, the CUSIP changed to 74291D 104.
• Management & operations unchanged: Business, assets, liabilities, fiscal year and the full board/executive team remain exactly the same post-domestication.
• Expert consents & exhibits: New opinions from Akin Gump (Ex. 5.1) and EY鈥檚 audit consent (Ex. 23.1) are filed; Delaware charter and by-laws are incorporated by reference.
• Indemnification framework: The filing details DGCL provisions and the company鈥檚 charter/by-law clauses that limit director & officer liability and permit broad indemnification, supplemented by D&O insurance and individual indemnification agreements.

No new securities are being offered and the amendment is largely administrative; it ensures continuous SEC registration and updates the governing law and disclosure cross-references to reflect the Delaware entity.

ICF International (ICFI) Form 4 filing: Director Michael J. Van Handel acquired 1,720 shares of common stock on 1 Jul 2025 through a restricted stock unit (RSU) grant under the company鈥檚 Amended and Restated 2018 Omnibus Incentive Plan. The RSUs carry a zero-dollar exercise price and will vest in equal quarterly increments on Sept 1, Dec 1, Mar 1 and Jun 1. Following the award, the director鈥檚 direct holdings rise to 16,254 shares. No derivative security activity was reported.

On 30 June 2025, MongoDB, Inc. (Nasdaq: MDB) convened its Annual Meeting of Stockholders and disclosed the voting results in an 8-K filing (Item 5.07).

• Board elections: Class II directors Francisco D鈥橲ouza (92.8% support), Charles M. Hazard, Jr. (62.8%), and Tom Killalea (89.2%) were elected to serve until the 2028 meeting.
• Say-on-pay: Executive compensation was approved on an advisory basis with 82.1% of votes cast in favor (47.5 M for vs. 10.1 M against).
• Say-on-pay frequency: Shareholders favored an annual advisory vote with 98.4% (56.7 M) supporting a one-year cadence.
• Auditor ratification: PricewaterhouseCoopers LLP was re-appointed as independent auditor for FY 2026 with 97.3% support.
• Charter amendment: An amendment limiting certain officer liabilities under Delaware law passed with 86.6% approval.

No other material business or financial results were reported. All proposals garnered substantial majority support, indicating broad shareholder alignment with current governance, compensation, and audit practices.

The filing is a Form 144 notice from The Hershey Company (HSY) disclosing a proposed insider sale. Rohit Grover intends to sell 1,333 common shares through Fidelity Brokerage Services on or about July 1, 2025 on the NYSE. The stake represents roughly 0.0009 % of the company鈥檚 147.99 million shares outstanding and is valued at approximately $233,275 based on the issuer鈥檚 reported market value. The shares were originally acquired via restricted-stock vesting between 2020-2023. A prior sale of the same amount occurred on June 9, 2025, generating $219,945 in gross proceeds.

No other material financial information, earnings data, or strategic developments are included; the notice is strictly procedural, indicating that the filer certifies no undisclosed adverse information and, if applicable, any Rule 10b5-1 plan adoption date.

The Hershey Company (HSY) 鈥� Form 144 filing discloses that affiliate filer Michele G. Buck intends to sell up to 19,290 common shares of Hershey on or about 01 July 2025 through Fidelity Brokerage Services on the NYSE. Based on the filing鈥檚 stated aggregate market value of $3,375,750, the implied reference price is about $175/share.

The shares originate from an option granted 01 Mar 2017 and exercised on the planned sale date. Hershey had 147,990,276 shares outstanding, so the proposed sale represents roughly 0.013 % of total shares.

The filing also notes that the same seller disposed of 31,210 shares on 30 May 2025 for gross proceeds of $5,018,568. Combining the completed and proposed transactions, the filer will have sold about 50,500 shares (~0.034 % of shares outstanding) within a three-month window, generating proceeds of roughly $8.4 million.

No information is provided on whether the trades are executed under a Rule 10b5-1 trading plan or whether any additional shares remain subject to option exercises. The Form 144 includes the customary representation that the seller possesses no undisclosed material adverse information.